Substance P and tachykinin agonists for treatment of Alzheimer's

Details Substance P and tachykinin agonists for treatment of Alzheimer's Substance P and tachykinin agonists for treatment of Alzheimer's

1990-07-27

1992-08-11

Wax, Robert A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, 530327, 530839, A61K 3742, A61K 3702, C07K 706, C07K 722

Patent

active

051378736

ABSTRACT:
Method for treatment of a disease in a patient characterized by accumulation of .beta.-amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist such as substance P. Methods for screening for compounds useful for treating such a disease are also disclosed.

REFERENCES:
patent: 3862114 (1975-01-01), Scandrett
patent: 4059693 (1977-11-01), Stewart
patent: 4728605 (1988-03-01), Fudenberg et al.
patent: 4816416 (1989-03-01), Averback
W. A. Banks et al., Brain Res. Bull. 15: 287-292, 1985.
N. W. Kowall et al., Proc. Natl. Acad. Sci. 88: 7247-7251, Aug. 1991.
Yates et al., Peptides and Amines in Alzheimer-type dementia and Down's syndrome, in Interdiscip. Top. Gerontol. 19: 175-83 (1985).
Abstracted in Chemical Abstracts 104:521, Ab#66941e (1986).
Berkow, editor, The Merck Manual, 14th Ed., pp. 981, 2249-2250 (1982).
Crystal et al., J. Neurochem. 38:1781, 1982.
Bouras et al., Alzheimer's Dis. Assoc. Disord. 4:24, 1990.
Quigley et al., Neuroscience 41:41, 1991.
McKhann et al., Neurology 34:939-944, 1984.
Wisniewski et al., Annals of Neurology 17(3):278-282, 1985.
Lai et al., Arch. Neurol. 46:849-853, 1989.
Schellenberg et al., Science 241:1507-1510, 1988.
St. George-Hyslop et al., Science 235:885-90, 1987.
Snider et al., Science, vol. 251, p. 435, 1991.
Watson et al., European Journal of Pharmacology, vol. 87, p. 77, 1983.
Penn et al., Neurology, vol. 38, p. 219, 1980.
Davies et al., Nature, vol. 288, p. 279, 1980.
Armstrong and Terry, Neuroscience Letters, vol. 58, p. 139, 1985.
Harbaugh et al., Neurosurgery, vol. 15, p. 514, 1984.
Rossor et al., Neuroscience Letters, vol. 20, p. 373, 1980.
Beal et al., Science vol. 229, p. 289, 1985.
Cramer et al., Journal of Neurology, vol. 232, p. 346, 1985.
Yates et al., Brain Research, vol. 258, p. 45, 1983.
Bar-Shavit et al., Biochemical and Biophysical Research Communications, vol. 94, p. 1445, 1980.
Lavielle et al., Biochemical Pharmacology, vol. 37, p. 41, 1988.
Armstrong et al., Neuroscience, vol. 31, p. 663, 1989.
Marx, Science, vol. 253, p. 266, 1991.
Wirak et al., Science, vol. 253, p. 323, 1991.
Clevens and Beal, Brain Research, vol. 486, p. 387, 1989.
Beal and Mazurek, Neurology, vol. 37, p. 1205, 1987.
Stanfield et al., Nature, vol. 315, p. 498, 1985.
Murray et al., Brain Research, vol. 459, p. 76, 1988.
Ferrier, Journal of Neurological Science, vol. 62, p. 159, 1983.
Robakis et al., Proceedings of the National Academy of Sciences USA, vol. 84, p. 419, 1987.
Kang et al., Nature, vol. 325, p. 733, 1987.
Sisodia et al., Science, vol. 248, p. 492, 1990.
Lee et al., European Journal of Pharmacology, vol. 130, p. 209, 1986.
Maggio, Annual Review of Neuroscience, vol. 11, p. 13, 1988.
Engberg et al., Nature, vol. 293, p. 222, 1981.
Mantyh et al., Journal of Neuroscience, vol. 9, p. 258, 1989.
Mai et al., Neuroscience, vol. 17, p. 709, 1986.
The Wall Street Journal, Aug. 15, 1991, p. B4.
Biotechnology News Watch, Aug. 5, 1991, pp. 2-4.
Yankner et al., 245 Science 417 (1989).
Whitson et al. 243 Science 1488 (1989).
Joachim et al. 341 Nature 226 (1989).

Affiliated with

Also associated with

Rating

Substance P and tachykinin agonists for treatment of Alzheimer's does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substance P and tachykinin agonists for treatment of Alzheimer's, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substance P and tachykinin agonists for treatment of Alzheimer's will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-346384